# A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

> **NCT05967689** · PHASE2 · RECRUITING · sponsor: **Taiho Oncology, Inc.** · enrollment: 220 (estimated)

## Conditions studied

- Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

## Interventions

- **DRUG:** TAS6417
- **DRUG:** CYP Cocktail
- **DRUG:** Transporter Cocktail

## Key facts

- **NCT ID:** NCT05967689
- **Lead sponsor:** Taiho Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-31
- **Primary completion:** 2028-08-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05967689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05967689, "A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05967689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*